16/03/2017
A new class of inhibitors against pain investigated at the ALBA synchrotron
A new class of inhibitors against pain investigated at the ALBA synchrotron
The pharmaceutical company ESTEVE (2,470 people, 916 million Euros income in 2016), the Universitat Autònoma de Barcelona (UAB) and the ALBA Synchrotron joined together to investigate the mechanism of action of new inhibitors against pain developed by the company.
Getting new information about the interactions, active site and mechanism of action of the developed drugs and the therapeutic target may help to the better understanding of the effects of the inhibitors and can provide key information to improve their properties. In that sense, the XALOC ALBA beam line offers a valuable tool for carrying out the corresponding experiments.
As a first step, the research will be carried out at the Protein Production Platform of the UAB to obtain the pure protein complexed with the inhibitors. Secondly, X-ray crystallography studies will be performed at the biolab and in ALBA.
This project is a good example of public-private collaboration that fosters the synergies and relationships between the industrial and academic sectors to advance research and innovation.
Getting new information about the interactions, active site and mechanism of action of the developed drugs and the therapeutic target may help to the better understanding of the effects of the inhibitors and can provide key information to improve their properties. In that sense, the XALOC ALBA beam line offers a valuable tool for carrying out the corresponding experiments.
As a first step, the research will be carried out at the Protein Production Platform of the UAB to obtain the pure protein complexed with the inhibitors. Secondly, X-ray crystallography studies will be performed at the biolab and in ALBA.
This project is a good example of public-private collaboration that fosters the synergies and relationships between the industrial and academic sectors to advance research and innovation.
More news
19/06/2014
ALBA synchrotron welcomes the one thousandth researcher
12/06/2014
€ 1.365 billion of foreign investment in the Catalan industry in 2013
03/06/2014
Barcelona Synchroton Park booth at the BioKorea 2014 exhibition in Seoul
27/05/2014
The new Barcelona Synchrotron Park bus shuttle completes its first six months
20/05/2014
SENER opens in the Barcelona Synchrotron Park its new corporate headquarters in Catalonia
15/05/2014
MATGAS, Air Products' leading R&D centre worldwide
home